I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Overall survival indirect treatment comparison between brig..:
Reckamp, KL
;
Lin, HM
;
Cranmer, H
...
Current Medical Research and Opinion, 2022, 38 (9), pp. 1587 - 1593. , 2022
Link:
https://repository.icr.ac.uk/handle/internal/5521
RT Journal T1
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L
UL https://suche.suub.uni-bremen.de/peid=base-ftinstcancerres:oai:repository.icr.ac.uk:internal_5521&Exemplar=1&LAN=DE A1 Reckamp, KL A1 Lin, HM A1 Cranmer, H A1 Wu, Y A1 Zhang, P A1 Kay, S A1 Walton, LJ A1 Shen, J A1 Popat, S A1 Camidge, DR PB TAYLOR & FRANCIS LTD YR 2022 K1 ALK+ NSCLC K1 alectinib K1 brigatinib K1 indirect treatment comparison K1 overall survival K1 Anaplastic Lymphoma Kinase K1 Carbazoles K1 Carcinoma K1 Non-Small-Cell Lung K1 Crizotinib K1 Humans K1 Lung Neoplasms K1 Organophosphorus Compounds K1 Piperidines K1 Protein Kinase Inhibitors K1 Pyrimidines JF Current Medical Research and Opinion, 2022, 38 (9), pp. 1587 - 1593 LK http://dx.doi.org/https://repository.icr.ac.uk/handle/internal/5521 DO https://repository.icr.ac.uk/handle/internal/5521 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)